Therefore, based on the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, treatment with Sodium–Glucose Cotransporter-2 (SGLT-2) inhibitors was initiated to reduce the risk of CV death and hospitalizations in patients with HF with reduced EF [14]. The gene discussed is SLC5A2; the disease is congestive heart failure.